Account
Eli Lilly & Co's longtime Chief Executive John Lechleiter will undergo surgery next Monday for a dilated aorta, but is expected to make a full recovery from the potentially dangerous condition and return to work this summer, the drugmaker said on Monday.Lilly Chief Financial Officer Derica Rice, 48, will assume the additional role of acting CEO during Lechleiter's surgery and recovery period, the Indianapolis drugmaker said.Lechleiter, 59, had no symptoms of the condition, but learned of it during recent unrelated medical testing, Lilly said.Rice and Lechleiter have worked closely together over the past four years in formulating plans to revive Lilly's earnings and sales after ongoing generic competition for some of its biggest drugs, including its Zyprexa schizophrenia drug.Many other large drugmakers have merged with another big pharmaceuticals company in order to withstand their patent cliffs. But Rice and Lechleiter have adamantly insisted that Lilly will remain independent, and de...
Bristol-Myers Squibb (NYSE:BMY) and Eli Lilly (NYSE:LLY) both reported weaker quarterly earnings and sales on Wednesday as they struggled to stem losses from patent ...
Eli Lilly & Co. (LLY) said its second-quarter profit declined 23%, as the drug maker continues to feel the effects of the recent patent expiration for antipsychotic ...
Shares of Eli Lilly (NYSE:LLY) touched a new high Tuesday morning after the company said it would resume share buybacks after a multi-year hiatus and finally complet...
Eli Lilly (NYSE:LLY) revealed on Wednesday a 25% drop in first-quarter net income, excluding one-time items, as sales of schizophrenia drug Zyprexa plunged after los...
Drug-industry executives touted on Thursday the investments they are making to discover new products in the face of a so-called patent cliff that will dramatically c...
Eli Lilly CEO John Lechleiter on new drugs in the company’s pipeline and Obama’s corporate tax proposal.
Drug makers Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) fell off the so-called "patent cliff," each reporting declines in fourth-quarter profits due to new generic c...
Eli Lilly (NYSE:LLY) said its fourth-quarter profit fell 27% on patent expirations but still beat Wall Street expectations, as the company tightened costs and grew i...
Eli Lilly & Co. (LLY) reported a 27% decline in fourth-quarter profit, as sales of antipsychotic Zyprexa took a big hit from new generic competition.The Indianapolis...
Eli Lilly (NYSE:LLY) on Thursday predicted a sharp drop in fiscal 2012 results when a number of its largest products are expected to lose patent exclusivity.The Indi...
Eli Lilly (NYSE:LLY) disclosed a 5% decrease in third-quarter profits amid higher costs on Thursday, but the big drug maker’s non-GAAP earnings met Wall Street’s exp...
President Barack Obama signed into law a patent overhaul bill Friday that backers say will curb frivolous lawsuits and help the U.S. Patent and Trademark Office do t...
Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to w...
Eli Lilly (NYSE:LLY) revealed a 4% decline in fourth-quarter profit due to ongoing effects of the so-called "patent cliff," but still topped Wall Street expectations...
Eli Lilly (NYSE:LLY) reaffirmed its in-line fiscal 2012 guidance on Friday and unveiled an upbeat outlook for the following year.The company also said it continues t...
Eli Lilly & Co. (LLY) plans to expand its Indianapolis insulin-manufacturing facilities in a multimillion-dollar investment to meet growing demand in the U.S.This ma...
Eli Lilly (NYSE:LLY) said on Friday that its experimental treatment for Alzheimer's disease failed to meet two late-stage studies' primary goals, however the drug gi...
Eli Lilly & Co. (LLY) said solanezumab, a highly anticipated potential treatment for Alzheimer's disease, failed to reach its set goals in either of two Phase 3 stud...
Two major U.S. drug companies took big hits to quarterly profits and sales because patent expirations for their top products cleared the way for generic competition....
